Venousthromboembolicevents(VTE)havebecomeaglobalpublichealthburden,withthegloballowmolecularweightheparin(LMWH)marketprojectedtoreachUSD5.52billionby2031ataCAGRof5.3%.AstwocoreLMWHproducts,EnoxaparinS
Venousthromboembolicevents(VTE),includingdeepveinthrombosisandpulmonaryembolism,remainamajorclinicalchallengeafterorthopedicsurgeriessuchastotalhipreplacement.Asahigh-qualitylowmolecularweightheparin,
ChondroitinSulfateSodium,anaturalglycosaminoglycan,hasbecomeapivotalingredientinpharmaceuticals,healthsupplements,andcosmeticsduetoitsremarkablebioactivities—includingjointfunctionimprovement,anti-in
Thromboembolicdiseaseshavebecomeaglobalpublichealthchallenge,withover50millionnewcardiovascularcasesannually.Asacoreanticoagulantdrug,HeparinSodiumiswidelyusedinhemodialysis,deepveinthrombosispreventi
Thromboembolicdiseases,includingdeepveinthrombosisandpulmonaryembolism,havebecomeaglobalpublichealthburden,affectingmillionsofpatientsannually.Asagold-standardlowmolecularweightheparin,EnoxaparinSodiu